Captrust Financial Advisors Uni Qure N.V. Transaction History

Captrust Financial Advisors

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	BUY	$13.15 - $20.45 $23,801 - $37,014	1,810 Added 1392.31%	1,940 $36,000
Q1 2022 May 16, 2022	SELL	$14.54 - $21.5 $6,746 - $9,976	-464 Reduced 78.11%	130 $2,000
Q4 2021 Feb 14, 2022	SELL	$20.24 - $36.01 $2,226 - $3,961	-110 Reduced 15.63%	594 $12,000
Q3 2021 Nov 16, 2021	BUY	$26.01 - $38.22 $5,306 - $7,796	204 Added 40.8%	704 $23,000
Q4 2020 Feb 16, 2021	BUY	$35.35 - $50.67 $17,675 - $25,335	500 New	500 $18,000
Q3 2020 Nov 17, 2020	SELL	$35.98 - $47.66 $17,990 - $23,830	-500 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$45.06 - $67.74 $22,530 - $33,870	500 New	500 $23,000

154

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $280M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.